Deal Discussions Distract From Disappointing Obesity Drug Sales

In this video, health-care analyst David Williamson looks at Vivus' first-quarter results and breaks it down into key takeaways for investors in both Vivus and its competitor Arena. Watch and find out why shares of the obesity-drug maker went up despite missing sales estimates and what it means now that Arena has received DEA scheduling.

Who will win the obesity drug market?
Can Vivus pick up its lagging sales and fend off the competition, or will Arena Pharmaceuticals reign supreme in the obesity space? If you're in the dark, grab copies of The Motley Fool's premium research reports on Vivus and Arena Pharmaceuticals to stay up to date. Senior biotech analyst Brian Orelli gives investors the must-know information, including an in-depth look at the obesity market and reasons to buy and sell both stocks. Click now for an exclusive look at Arena and Vivus -- complete with a full year of free updates -- today.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 15, 2013, at 8:44 AM, MRJOSEPHD wrote:

    Eisai guides to $200M in their FY2013 for Belviq

    I don't believe anyone has posted this yet but I just had a chance to listen to Eisai's earnings call and there is a golden nugget in the QA session. Sorry if someone already posted but I don't believe they have.

    http://www.net-ir.ne.jp/e-pre/4523qa1305e/wn/pre_start.html

    Question 4. When asked by Credit Suisse about slide 11 in the presentation http://eisai.com/pdf/eir/emat/e4523_130513.pdf and how they will achieve these growth numbers, Eisai's CEO says Belviq is not called out in that slide because it was not available yet but he would like to see at least $200M from Belviq in FY2013 (end of March 2014.)

    Lonnel Coats goes on to discuss the importance of the new AACE guidelines and also confirms Medco coverage.

    By June 11, Belviq will be available in 20K pharmacies. Within the first 30 days on the market, the sales force will have touched 20K physicians. "We will penetrate this market very quickly."

    If you have Belviq do $200M over the next 8mo and Qsymia does $20M, maybe the street will then start to get it. And if they say $200M, they should be confident that is a conservative number for them.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2425208, ~/Articles/ArticleHandler.aspx, 11/20/2014 9:53:04 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 17,719.00 33.27 0.19%
S&P 500 2,052.75 4.03 0.20%
NASD 4,701.87 26.16 0.56%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

11/20/2014 4:00 PM
ARNA $4.18 Up +0.10 +2.45%
Arena Pharmaceutic… CAPS Rating: ***
VVUS $3.17 Up +0.13 +4.28%
VIVUS, Inc. CAPS Rating: **

Advertisement